CYduct Diagnostics, Inc., a healthcare company, develops, produces, and markets medical devices for the assessment, identification, diagnosis and treatment of breast cancer. The company offers HALO system, a noninvasive device that utilizes proprietary technology to obtain breast fluid; and MammoView, a fiberoptic technology with the ability to view and collect cells and other abnormalities. It also provides women and clinicians with technology that will lead the Intraductal approach to breast cancer and improvement in breast healthcare. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was incorporated in 1986 and is based in Westport, Connecticut.
Frequently asked questions
What sector does Cyduct Diagnostics Inc (CYDX) operate in?
Cyduct Diagnostics Inc belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Cyduct Diagnostics Inc (CYDX) current stock price?
As of the latest data, Cyduct Diagnostics Inc stock price is $0.50, with a previous close of $0.50.
What is Cyduct Diagnostics Inc (CYDX) current market capitalization?
Cyduct Diagnostics Inc market cap is approximately 6.39 million.
What is Cyduct Diagnostics Inc (CYDX) Earnings Per Share (EPS)?
The trailing EPS is $0.77.
What is Cyduct Diagnostics Inc (CYDX) Price-to-Earnings (P/E) ratio?
Cyduct Diagnostics Inc current P/E ratio is 0.65.
What is Cyduct Diagnostics Inc (CYDX) EBITDA?
Cyduct Diagnostics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 60.70 thousand.
Does Cyduct Diagnostics Inc (CYDX) pay dividends?
No. Cyduct Diagnostics Inc does not pay a dividend.
What is Cyduct Diagnostics Inc (CYDX) beta (volatility) score?
Cyduct Diagnostics Inc has a beta of 0.272, indicating lower volatility than the overall market.
